Dr. Andrew Place, MD, PhD
Claim this profileDana-Farber Cancer Institute
Studies Childhood Cancer
Studies Lymphoma
11 reported clinical trials
26 drugs studied
Area of expertise
1Childhood Cancer
BCR-ABL1 positive
Stage IV
BCR-ABL1 T315I positive
2Lymphoma
BCR-ABL1 positive
Stage IV
BCR-ABL1 T315I positive
Affiliated Hospitals
Clinical Trials Andrew Place, MD, PhD is currently running
Venetoclax Combination Therapy
for Blood Cancers
This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived from myelodysplastic syndrome (MDS/AML), and acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL). The names of the study drugs involved in this study are below. Please note this is a list for the study as a whole, participants will receive drugs according to disease cohort. * Venetoclax * Azacitidine * Cytarabine * Methotrexate * Hydrocortisone * Leucovorin * Dexamethasone * Vincristine * Doxorubicin * Dexrazoxane * Calaspargase pegol * Hydrocortisone
Recruiting1 award Phase 1
Selinexor + Venetoclax + Chemotherapy
for Acute Myeloid Leukemia
The purpose of this study is to test the safety and determine the best dose of venetoclax and selinexor when given with chemotherapy drugs in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that has come back (relapsed) or did not respond to treatment (refractory). Primary Objective * To determine the safety and tolerability of selinexor and venetoclax in combination with chemotherapy in pediatric patients with relapsed or refractory AML or ALAL. Secondary Objectives * Describe the rates of complete remission (CR) and complete remission with incomplete count recovery (CRi) for patients treated with selinexor and venetoclax in combination with chemotherapy at the recommended phase 2 dose (RP2D). * Describe the overall survival of patients treated at the RP2D. Exploratory Objectives * Explore associations between leukemia cell genomics, BCL2 family member protein quantification, BH3 profiling, and response to therapy as assessed by minimal residual disease (MRD) and variant clearance using cell-free deoxyribonucleic acid (DNA) (cfDNA). * Describe the quality of life of pediatric patients undergoing treatment with selinexor and venetoclax in combination with chemotherapy and explore associations of clinical factors with patient-reported quality of life outcomes. * Describe the clinical and genetic features associated with exceptional response to the combination of venetoclax and selinexor without the addition of chemotherapy.
Recruiting1 award Phase 1
More about Andrew Place, MD, PhD
Clinical Trial Related5 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Andrew Place, MD, PhD has experience with
- Cytarabine
- Dexamethasone
- Methotrexate
- Venetoclax
- Fludarabine
- Oncaspar
Breakdown of trials Andrew Place, MD, PhD has run
Childhood Cancer
Lymphoma
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andrew Place, MD, PhD specialize in?
Andrew Place, MD, PhD focuses on Childhood Cancer and Lymphoma. In particular, much of their work with Childhood Cancer has involved BCR-ABL1 positive patients, or patients who are Stage IV.
Is Andrew Place, MD, PhD currently recruiting for clinical trials?
Yes, Andrew Place, MD, PhD is currently recruiting for 3 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Andrew Place, MD, PhD has studied deeply?
Yes, Andrew Place, MD, PhD has studied treatments such as Cytarabine, Dexamethasone, Methotrexate.
What is the best way to schedule an appointment with Andrew Place, MD, PhD?
Apply for one of the trials that Andrew Place, MD, PhD is conducting.
What is the office address of Andrew Place, MD, PhD?
The office of Andrew Place, MD, PhD is located at: Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States. This is the address for their practice at the Dana-Farber Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.